Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3

a 1-year double-blind RCT in postmenopausal women

Helen M Macdonald, Adrian D Wood, Lorna S Aucott, Alison J Black, William D Fraser, Alexandra Mavroeidi, David M Reid, Karen R Secombes, William G Simpson, Frank Thies

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Few year-long vitamin D supplementation trials exist that match seasonal changes. The aim of this study was to determine whether daily oral vitamin D3 at 400 IU or 1000 IU compared with placebo affects annual BMD change in postmenopausal women in a 1-year double blind placebo controlled trial in Scotland. Caucasian women aged 60-70 y (n = 305) were randomized to one of two doses of vitamin D or placebo. All participants started simultaneously in January/February 2009, attending visits at bi-monthly intervals with 265 (87%) women attending the final visit; and an additional visit 1 month after treatment cessation. BMD (Lunar iDXA) and 1,25-dihydroxyvitamin D[1,25(OH)2 D], N-terminal propeptide of type 1 collagen [P1NP], C-terminal telopeptide of type I collagen [CTX] and fibroblast growth factor-23 [FGF23] were measured by immunoassay at the start and end of treatment. Circulating PTH, serum Ca and total 25-hydroxyvitamin D [25(OH)D] (latter by tandem mass spectrometry) were measured at each visit. Mean BMD loss at the hip was significantly less for the 1000 IU vitamin D group (0.05 ± 1.46%), compared to the 400 IU vitamin D or placebo groups (0.57 ± 1.33% and 0.60 ± 1.67%, respectively) (p 
Original languageEnglish
Pages (from-to)2202-2213
Number of pages12
JournalJournal of Bone and Mineral Research
Volume28
Issue number10
Early online date18 Sep 2013
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Pelvic Bones
Cholecalciferol
Vitamin D
Placebos
Withholding Treatment
Scotland
Collagen Type I
Tandem Mass Spectrometry
Immunoassay
Hip
Serum

Keywords

  • vitamin D
  • randomised controlled trial
  • bone loss
  • bone turnover markers
  • postmenopausal women

Cite this

Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3 : a 1-year double-blind RCT in postmenopausal women. / Macdonald, Helen M; Wood, Adrian D; Aucott, Lorna S; Black, Alison J; Fraser, William D; Mavroeidi, Alexandra; Reid, David M; Secombes, Karen R; Simpson, William G; Thies, Frank.

In: Journal of Bone and Mineral Research, Vol. 28, No. 10, 10.2013, p. 2202-2213.

Research output: Contribution to journalArticle

Macdonald, Helen M ; Wood, Adrian D ; Aucott, Lorna S ; Black, Alison J ; Fraser, William D ; Mavroeidi, Alexandra ; Reid, David M ; Secombes, Karen R ; Simpson, William G ; Thies, Frank. / Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3 : a 1-year double-blind RCT in postmenopausal women. In: Journal of Bone and Mineral Research. 2013 ; Vol. 28, No. 10. pp. 2202-2213.
@article{025fb302b9d844ad849921cf445dfd1c,
title = "Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women",
abstract = "Few year-long vitamin D supplementation trials exist that match seasonal changes. The aim of this study was to determine whether daily oral vitamin D3 at 400 IU or 1000 IU compared with placebo affects annual BMD change in postmenopausal women in a 1-year double blind placebo controlled trial in Scotland. Caucasian women aged 60-70 y (n = 305) were randomized to one of two doses of vitamin D or placebo. All participants started simultaneously in January/February 2009, attending visits at bi-monthly intervals with 265 (87{\%}) women attending the final visit; and an additional visit 1 month after treatment cessation. BMD (Lunar iDXA) and 1,25-dihydroxyvitamin D[1,25(OH)2 D], N-terminal propeptide of type 1 collagen [P1NP], C-terminal telopeptide of type I collagen [CTX] and fibroblast growth factor-23 [FGF23] were measured by immunoassay at the start and end of treatment. Circulating PTH, serum Ca and total 25-hydroxyvitamin D [25(OH)D] (latter by tandem mass spectrometry) were measured at each visit. Mean BMD loss at the hip was significantly less for the 1000 IU vitamin D group (0.05 ± 1.46{\%}), compared to the 400 IU vitamin D or placebo groups (0.57 ± 1.33{\%} and 0.60 ± 1.67{\%}, respectively) (p ",
keywords = "vitamin D, randomised controlled trial, bone loss, bone turnover markers, postmenopausal women",
author = "Macdonald, {Helen M} and Wood, {Adrian D} and Aucott, {Lorna S} and Black, {Alison J} and Fraser, {William D} and Alexandra Mavroeidi and Reid, {David M} and Secombes, {Karen R} and Simpson, {William G} and Frank Thies",
note = "Copyright {\circledC} 2013 American Society for Bone and Mineral Research.",
year = "2013",
month = "10",
doi = "10.1002/jbmr.1959",
language = "English",
volume = "28",
pages = "2202--2213",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "WILEY-BLACKWELL",
number = "10",

}

TY - JOUR

T1 - Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3

T2 - a 1-year double-blind RCT in postmenopausal women

AU - Macdonald, Helen M

AU - Wood, Adrian D

AU - Aucott, Lorna S

AU - Black, Alison J

AU - Fraser, William D

AU - Mavroeidi, Alexandra

AU - Reid, David M

AU - Secombes, Karen R

AU - Simpson, William G

AU - Thies, Frank

N1 - Copyright © 2013 American Society for Bone and Mineral Research.

PY - 2013/10

Y1 - 2013/10

N2 - Few year-long vitamin D supplementation trials exist that match seasonal changes. The aim of this study was to determine whether daily oral vitamin D3 at 400 IU or 1000 IU compared with placebo affects annual BMD change in postmenopausal women in a 1-year double blind placebo controlled trial in Scotland. Caucasian women aged 60-70 y (n = 305) were randomized to one of two doses of vitamin D or placebo. All participants started simultaneously in January/February 2009, attending visits at bi-monthly intervals with 265 (87%) women attending the final visit; and an additional visit 1 month after treatment cessation. BMD (Lunar iDXA) and 1,25-dihydroxyvitamin D[1,25(OH)2 D], N-terminal propeptide of type 1 collagen [P1NP], C-terminal telopeptide of type I collagen [CTX] and fibroblast growth factor-23 [FGF23] were measured by immunoassay at the start and end of treatment. Circulating PTH, serum Ca and total 25-hydroxyvitamin D [25(OH)D] (latter by tandem mass spectrometry) were measured at each visit. Mean BMD loss at the hip was significantly less for the 1000 IU vitamin D group (0.05 ± 1.46%), compared to the 400 IU vitamin D or placebo groups (0.57 ± 1.33% and 0.60 ± 1.67%, respectively) (p 

AB - Few year-long vitamin D supplementation trials exist that match seasonal changes. The aim of this study was to determine whether daily oral vitamin D3 at 400 IU or 1000 IU compared with placebo affects annual BMD change in postmenopausal women in a 1-year double blind placebo controlled trial in Scotland. Caucasian women aged 60-70 y (n = 305) were randomized to one of two doses of vitamin D or placebo. All participants started simultaneously in January/February 2009, attending visits at bi-monthly intervals with 265 (87%) women attending the final visit; and an additional visit 1 month after treatment cessation. BMD (Lunar iDXA) and 1,25-dihydroxyvitamin D[1,25(OH)2 D], N-terminal propeptide of type 1 collagen [P1NP], C-terminal telopeptide of type I collagen [CTX] and fibroblast growth factor-23 [FGF23] were measured by immunoassay at the start and end of treatment. Circulating PTH, serum Ca and total 25-hydroxyvitamin D [25(OH)D] (latter by tandem mass spectrometry) were measured at each visit. Mean BMD loss at the hip was significantly less for the 1000 IU vitamin D group (0.05 ± 1.46%), compared to the 400 IU vitamin D or placebo groups (0.57 ± 1.33% and 0.60 ± 1.67%, respectively) (p 

KW - vitamin D

KW - randomised controlled trial

KW - bone loss

KW - bone turnover markers

KW - postmenopausal women

U2 - 10.1002/jbmr.1959

DO - 10.1002/jbmr.1959

M3 - Article

VL - 28

SP - 2202

EP - 2213

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 10

ER -